Medicare Now Covers GLP-1 Weight Loss Drugs: What Seniors Need to Know About the $50 Monthly Copay
Millions of Seniors Gain Access to Affordable Weight-Loss Medications
In a historic shift in public health policy, Medicare has officially begun covering GLP-1 weight-loss drugs for the first time as of July 1, 2026. The new program, called the Medicare GLP-1 Bridge, offers eligible beneficiaries access to blockbuster medications such as Wegovy, Zepbound, and Foundayo for a flat monthly copay of just $50.
This landmark change opens the door for millions of older Americans who previously had to pay hundreds of dollars out of pocket for these treatments. According to the Kaiser Family Foundation (KFF), an estimated 3.8 million Medicare beneficiaries meet the eligibility requirements under the new program.
What Is the Medicare GLP-1 Bridge Program?
The GLP-1 Bridge is a temporary 18-month pilot program running from July 1, 2026, through December 31, 2027. It is administered by the Centers for Medicare & Medicaid Services (CMS) and works outside standard Medicare Part D coverage. The program leverages a specific legal provision that allows the federal government to establish temporary drug coverage initiatives.
“Medicare is not changing the law right now,” Juliette Cubanski, vice president and director of Medicare policy at KFF, explained to CBS News. “What it’s doing is taking advantage of a specific section of the law that gives the federal government the ability to stand up a temporary program.”
Before this change, Medicare could only cover GLP-1 drugs for patients using them to treat conditions like Type 2 diabetes or cardiovascular disease. Weight-loss drugs prescribed solely for obesity were explicitly excluded. The GLP-1 Bridge marks the first time Medicare will help pay for these drugs when prescribed for weight management alone.
Which Drugs Are Covered?
Medicare’s GLP-1 Bridge program covers the following medications:
- Foundayo® (tablet form) — Eli Lilly’s daily oral weight-loss medication
- Wegovy® (injection or tablet forms) — Novo Nordisk’s weekly injectable and oral semaglutide
- Zepbound® (KwikPen form only) — Eli Lilly’s weekly tirzepatide injection
It is important to note that the program does not cover single-dose Zepbound vials or pens. The program also does not cover GLP-1 drugs prescribed for other conditions, such as Ozempic for diabetes, although those remain covered under standard Part D plans.
Who Qualifies for the $50 Monthly Copay?
To be eligible, you must be 18 or older and have Medicare Part D coverage through any qualifying plan, including standalone drug plans, Medicare Advantage plans with drug coverage, Special Needs Plans, and employer group waiver plans.
Clinical eligibility is determined by body mass index (BMI) and additional health conditions at the time of starting GLP-1 therapy:
Category 1: BMI of 35 or higher
Patients with a BMI of 35 or more qualify regardless of additional health conditions.
Category 2: BMI between 30 and 34.99
Patients in this range qualify if they also have at least one of the following conditions:
- Diastolic heart failure (heart failure with preserved ejection fraction)
- Uncontrolled high blood pressure
- Chronic kidney disease (stage 3a or higher)
- Prediabetes
- A previous heart attack or stroke
- Peripheral artery disease with symptoms
Category 3: BMI between 27 and 29.99
Patients in this overweight category qualify if they also have prediabetes, a history of heart attack or stroke, or symptomatic peripheral artery disease.
How to Access the Program
Eligible patients should follow these steps:
- Speak with your healthcare provider — Discuss whether a GLP-1 drug is appropriate for your health profile
- Get a prescription — Your provider must prescribe one of the covered GLP-1 drugs
- Complete prior authorization — Your provider must submit a prior authorization request to Medicare confirming your BMI and qualifying conditions
- Fill your prescription — The pharmacy will process your prescription at the $50 monthly copay
Your provider must also certify that you are using the GLP-1 drug as part of a lifestyle program focusing on diet and exercise. The prior authorization, once approved, remains valid through December 31, 2027, including for refills and dose changes — as long as you do not switch to a different GLP-1 drug.
What to Know About Costs
The $50 monthly copay is a significant reduction from the typical out-of-pocket cost of around $350 per month. However, there are important caveats:
- The copay does not count toward your Part D deductible or your annual $2,100 out-of-pocket cap
- Patients cannot apply manufacturer coupons or discounts to further reduce the $50 copay
- You do not need to meet your deductible first — the $50 rate applies immediately
What Happens After 2027?
The temporary nature of the program raises questions about long-term access. Unless CMS issues an extension or Congress changes the law, patients could lose Medicare coverage for GLP-1 weight-loss drugs at the end of 2027. Some experts suggest drug manufacturers may adjust pricing to maintain access, but nothing is guaranteed.
“In the short term, we have this temporary program, and then no clear path forward yet as to what will happen at the end of 2027,” Cubanski noted.
Frequently Asked Questions
Can I get GLP-1 drugs through Medicare if I have diabetes?
If you already have Type 2 diabetes and are taking a GLP-1 drug like Ozempic, your standard Medicare Part D plan already covers it. You would not qualify for the Bridge program, but you do not need it — your existing coverage remains in place.
Does Medicare cover compounded GLP-1 drugs?
No. The Bridge program only covers FDA-approved brand-name drugs listed above. Compounded semaglutide or tirzepatide from compounding pharmacies is not eligible.
Will I need a new prescription every month?
No. Once your prior authorization is approved, it covers refills and dose changes until December 31, 2027, unless you switch to a different GLP-1 drug.
What if my Medicare Advantage plan does not participate?
The program applies nationwide. If your plan is an eligible Part D plan, you should have access. Contact your plan or call 1-800-MEDICARE if you encounter issues.
The Bottom Line
The Medicare GLP-1 Bridge program represents a major step forward in making weight-loss treatments accessible to older Americans who need them most. For the millions of seniors living with obesity and related health conditions, this program offers a more affordable path to better health — at least for the next 18 months.
If you or a loved one may qualify, the best first step is to speak with a healthcare provider about whether GLP-1 therapy is right for you. With the $50 monthly copay and streamlined prior authorization process, there has never been a better time to explore your options.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
